BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025
Rhea-AI Summary
BioCardia (NASDAQ:BCDA), a company specializing in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, has scheduled its Q1 2025 corporate update and financial results conference call for May 14, 2025, at 4:30 PM EDT. The call will include management's formal remarks followed by a Q&A session.
Participants can pre-register online or join by phone: U.S. callers should dial 1-833-316-0559, while international callers should use 1-412-317-5730. A live webcast will be available, and replay options will be accessible until May 28, 2025, through both web and telephone platforms.
Positive
- None.
Negative
- None.
News Market Reaction – BCDA
On the day this news was published, BCDA declined 0.35%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended March 31, 2025 by conference call on Wednesday, May 14, 2025 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session.
Participants can register for the conference by navigating to https://dpregister.com/sreg/10199950/ff25def0f6.
Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=ZrMeNX6o.
A webcast replay of the call will be available approximately one hour after the end of the call through approximately May 28, 2025 at the following link: https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will also be available and may be accessed by calling 1-877-344-7529 (domestic), 1-412-317-0088 (international) or 855-669-9658 (Canada) by using access code 4465715.
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit www.biocardia.com.
MEDIA CONTACT: Miranda Peto, Investor Relations mpeto@biocardia.com (650) 226-0120 INVESTOR CONTACT: David McClung, Chief Financial Officer investors@biocardia.com (650) 226-0120
FAQ
When is BioCardia (BCDA) reporting Q1 2025 earnings?
How can I join BioCardia's Q1 2025 earnings call?
What is the replay access code for BioCardia's Q1 2025 earnings call?
Until when is BioCardia's Q1 2025 earnings call replay available?
